Document Detail


The Efficacy and Safety of Sildenafil in Patients With Pulmonary Arterial Hypertension Associated With the Different Types of Congenital Heart Disease.
MedLine Citation:
PMID:  21678455     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: The difference in underlying pathophysiology in different congenital heart disease (CHD) may have an influence on clinical outcome. It remains unclear whether the effect of sildenafil on pulmonary arterial hypertension (PAH) varies in different types of CHD. HYPOTHESIS: The potential effect of sildenafil on pulmonary arterial hypertension related to CHD may be associated with shunt location. METHODS: In this 12-week, prospective, open label, multicenter trial, 55 patients with CHD were divided into the 3 groups: atrial septal defects group (ASD, n = 15), ventricular septal defects group (VSD, n = 24), and patent ductus arteriosus group (PDA, n = 16). Exercise capacity, hemodynamic parameters, and arterial oxygen saturation were assessed at baseline and after sildenafil therapy (25 mg, 3 times daily). RESULTS: Six-minute walk distance significantly increased from 377.2 ± 68.7 m to 436.0 ± 70.4 m in patients with ASD, from 371.2 ± 66.0 m to 413.7 ± 83.1 m in VSD, and from 384.3 ± 90.2 m to 440.9 ± 71.8 m in PDA (P<0.01, respectively). Moreover, sildenafil also improved the pulmonary vascular resistance and pulmonary blood flow index in the 3 groups, whereas no significant changes in systemic vascular resistance and systemic arterial pressure were observed. However, arterial oxygen saturation was significantly improved in the ASD group only. The incidence of adverse events was similar among the 3 groups. CONCLUSIONS: Sildenafil therapy seems to be effective and safe for PAH secondary to ASD, VSD, and PDA, although some clinical and hemodynamic parameters were changed in a different manner among the 3 groups. © 2011 Wiley Periodicals, Inc. This study was partly supported by National Grant from The Ministry of Science and Technology (2006BAI01A07) and Capital Development Scientific Fund (2005-1018). The authors have no other funding, financial relationships, or conflicts of interest to disclose. Study Group participants are listed in the Supporting Information Appendix.
Authors:
Wei-Jie Zeng; Xian-Ling Lu; Chang-Ming Xiong; Guang-Liang Shan; Zhi-Hong Liu; Xin-Hai Ni; Qing Gu; Zhi-Hui Zhao; Jian-Jun Li; Jian-Guo He;
Related Documents :
8960505 - Experimental results with endovascular irradiation via a radioactive stent.
1869725 - Restenosis after coronary angioplasty: a multivariate statistical model to relate lesio...
21561845 - The effects of testosterone on isolated sheep coronary artery.
18031845 - Two-year outcome of the use of paclitaxel-eluting stents in aorto-ostial lesions.
2934585 - Correction of taussig-bing malformation by intraventricular conduit.
11519545 - Rupture of an aneurysm of the coronary sinus of valsalva: diagnosis by helical ct angio...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-6-15
Journal Detail:
Title:  Clinical cardiology     Volume:  -     ISSN:  1932-8737     ISO Abbreviation:  -     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-6-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7903272     Medline TA:  Clin Cardiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2011 Wiley Periodicals, Inc.
Affiliation:
Center for Diagnosis and Management of Pulmonary Vascular Diseases, Department of Cardiology, Cardiovascular Institute, Fu Wai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Appropriate Therapy But Not Inappropriate Shocks Predict Survival in Implantable Cardioverter Defibr...
Next Document:  Enantioresolution of five ?-blockers by reversed-phase high-performance liquid chromatography using ...